Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445062 · ClinicalTrials.gov registry record · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,130
- Enrollment target
- 20
- Study locations
NCT06445062: Recruiting Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
NCT06445062 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 1,130 participants, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06445062, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Primary Outcome
Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.
Conditions Studied
Interventions
- DRUG cetuximab
- DRUG RMC-6236
- DRUG bevacizumab
- DRUG mFOLFOX6 regimen
- DRUG mFOLFIRINOX regimen
Study Locations (20)
Arizona
- Ironwood Cancer and Research Centers - Chandler
- Mayo Clinic Hospital - Phoenix
- HonorHealth Research Institute - Scottsdale
California
- UC San Diego Moores Cancer Center - La Jolla
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center - Los Angeles
- UCLA Hematology/Oncology- Santa Monica - Los Angeles
Florida
- Mayo Clinic Cancer Center - Jacksonville
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Nebraska
- Nebraska Cancer Specialists - Omaha
- University of Nebraska Medical Center - Omaha
New York
- Northwell Health / RJ Zuckerberg Cancer Center - Lake Success
- Columbia University Medical Center - New York
Colorado
- University of Colorado Hospital-Anschutz Cancer Pavilion - Aurora
Connecticut
- Yale-New Haven Hospital-Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 1 |
What NCT06445062 shows while recruiting
NCT06445062 is an interventional study that assigns participants to a tested intervention. Its 1,130 participants enrollment target places it among the larger protocols in the corpus, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (27% lower).
The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which cetuximab is the first listed.
NCT06445062 names 20 study sites across 12 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06445062 about?
NCT06445062 is a clinical study titled "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors". The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + ...
What is the current status of trial NCT06445062?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,130 participants. The study started on 2024-05-24. Estimated completion is 2027-07-15.
What conditions does trial NCT06445062 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, CRC.
What interventions are being tested in trial NCT06445062?
The interventions under investigation include: cetuximab (DRUG), RMC-6236 (DRUG), bevacizumab (DRUG), mFOLFOX6 regimen (DRUG), mFOLFIRINOX regimen (DRUG).
Who is sponsoring clinical trial NCT06445062?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445062 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06445062's enrollment target sits among peer trials
1,130 43rd of 381 higher than 339 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
- NCT05438329 · 1,123 participants · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI